12 th <strong>Congress</strong> <strong>of</strong> <strong>the</strong> <strong>European</strong> <strong>Hematology</strong> Association Urbaez, A., 1330 Urbaniak, D., 0981 Urbano, A., 0728 Urbano-Ispizua, A., 0378, 0379, 0394, 0921 Urbanska-Rys, H., 0276 Urdanoz, M.J., 1371 Urosevic, I., 1192 Usala, E, 0549, 0650 Usardi, P., 0205 Usnarska-Zubkiewicz, L., 1214, 1528 Ussowicz, M., 0585 Ustunsoz, B., 0088 Usurelu, D., 1232 Uysal, A.U., 1447 Uysal, H., 1319 Uysalgil, N., 1033 Uziel, L., 0715, 0867 Uzunov, M., 0617 V Vaccher, E., 0867 Vaddi, K., 0324 Vadikolia, C., 1534 Vagima, Y., 0431 Vainchenker, W., 0149, 0237, 0249, 0413, 0443 Vaiopoulos, G., 0393, 1186 Vaisiraygani, A., 1224 Vakalopoulou, S., 0638, 1263, 1512 Valantin, M.A., 0722 Valcarcel, D., 0119 Valdré, L., 0092, 0341 Valencia, A., 1063 Valencia, E., 0727 Valent, P., 0033, 0070, 0220, 0232, 0238, 0311, 0732, 0969, 1112, 1360 Valenta, R., 0311 Valente, D., 0650 Valentini, G.C., 0784, 1023 Valeri, F., 0756, 1191 Vales, A., 0033, 0070, 0311, 0732, 1360 Valeyre, D., 0642 Valgañón, M., 0097 Valk, P.J.M., 0900 Valk, P., 0478 Válková, V ., 0994 Valkovic, T., 1369 Vallantin, X., 1291 Vallejo, C., 0839 Vallenga, E., 0399 Vallet, S., 0312 Valpreda, A., 1191 Valsami, S., 0180 Valteau-Couanet, D., 0503 Valvano, M.R., 1196 Van Beek, E.M., 0478 Van Binsbergen, E., 1211 Van de Loosdrecht, A.A., 0220, 0478 Van de Velde, H., 0404 Van den Akker, M., 0018 Van den Berg, T.K., 0478 Van den Driessche, M., 0073 Van den Elsen, P.J., 0929 Van den Heuvel-Eibrink, M.M., 0045, 0225, 0957 Van Den Neste, E., 0379 Van der Burg, M., 0367 Van der Schoot, C.E., 0350 Van der Velden, V.J.V., 0421 Van Dongen, J.J.M., 0095, 0367, 0421, aj | haematologica/<strong>the</strong> hematology journal | 2007; 92(s1) 0873 Van Droogenbroeck, J., 0681 Van Drunen, E., 0900 Van Eggermond, M.C.J.A., 0929 Van Enk, G.J., 1320 Van Erps, J., 1206 Van Gastel-Mol, E.J., 0095 Van Heijst, A., 0085 Van Lindt, M., 0076 Van Lint, M.T., 0049, 0438 Van Loon, J., 0367 Van Norden, Y., 0900 Van Olmen, A., 0073 Van Solinge, W.W., 0785 Van Tol, M., 0421 Van Tornout, J.M.A., 0026, 0859 Van Vlierberghe, P., 0442 Van Wering, E.R., 0225, 0421, 0957 Van Wesel, A.C., 0785 Van Wijk, R., 0785 Van Wulfften Pal<strong>the</strong>, A.F.Y., 0350 Van Zantwijk, Ch., 0481 Van Zutven, L., 0141 Vance, G.H., 0381 Vandebroek, A., 0768 Vandenberghe, P., 0442, 0875 Vanhoorelbeke, K., 0838 Vannier, J.P., 1100 Vannucchi, A.M., 0251, 0645, 0667, 0896, 0897 Vanura, K., 0008 Varaldo, R., 0049, 0177, 1538 Varasano, E., 0138 Varela, C., 0303 Varet, B., 0553 Vargas, M., 0174, 0699 Variami, E., 0179, 0393 Varis, I., 0853 Varkonyi, J., 1026 Varlamova, E.Yu., 0740 Varma, N., 1394, 1050 Varma, S., 1050, 1394 Varotto, S., 1024 Vartholomatos, G., 1198, 1309 Vasilache, V., 1398, 1468 Vasiljev, S., 0818 Vasilyeva, M.N., 1165 Vásová, I., 0281, 0702 Vassal, G., 0503, 0999 Vassart, G., 0792 Vassilakopoulos, T.P., 0117, 0179, 0287, 0393, 0685, 0714, 0885, 1186, 1256 Vassilieff, D., 0222, 0427 Vassiliou, V., 1543 Vassord, C., 1040 Vassou, A., 1081, 1399 Vatter, C., 0694 Vaughan, R., 0572 Vavatsi-Christaki, N., 1080, 1311 Vaz, A., 0246 Vazao, H., 0813 Vazquez, I., 0869 Vcelikova, S., 1010 Vedina, L., 1450 Vedovelli, C., 0201 Vehma, J., 0899 Vekh<strong>of</strong>f, A., 0029 Vela, C., 1291 Velano, C.E.E., 0614, 1463 Velasco, F., 0163, 0469 Velastegui, K., 0123 Velegraki, M., 0064, 0437 Vellano, C., 0963 Veltroni, M., 0020 Vendiadi, K., 0801 Venditti, A., 0031, 0058, 0361, 0486, 0494 Vendramin, C., 1088 Vener, C., 0242 Venizelos, I., 0638, 1263, 1418 Venturini, L., 0240 Verachtert, H., 0875 Verbrugge, H., 0997 Vercauteren, S., 0221 Vercellati, C., 1325 Verdelli, D., 0692 Verdi, H., 0344 Verdier, F., 0931 Verdonck, L.F., 0453 Verducci Galletti, B., 0576 Verfaillie, C.M., 0432 Verger, E., 0842 Verhaaf, B., 0225, 0873 Verhoef, G., 0376 Verkholevsky, Y., 0457 Verlaak, R., 0085 Vermylen, C., 0376 Vernant, J.P., 0362 Verrou, E., 0079, 0657, 1289 Verschaeren, J., 0073 Verstandig, A., 0580, 0956 Verstovsek, S., 0651, 0927 Verzhbitskaya, T., 1437 Vesely, P., 0295, 0919, 0920 Vetesnikova, E., 0262 Vexler, A., 0187 Vey, N., 0055, 0222, 0427, 0428, 0455, 0485, 0490, 0497, 1047 Veys, P., 0370 Viale, P., 0201 Viardot, A., 0010 Viarengo, G.L., 0645 Vicari, L., 0036 Vicari, L., 1275 Vicente, C., 0097, 0869 Vicente, V., 1053 Vidán, J., 0788, 0793, 1160 Vidlakova, P., 0197, 0277, 0947, 1471 Vidovic, A., 0683, 1069, 1104, 1361, 1515 Vieira, E., 0161 Vieira, L., 0246 Viens, P., 0158 Vigna, E., 0116, 0255, 0641, 0675 Vigneri, P., 0533 Vignoli, A., 0057, 0895 Vignolo, L., 0049, 1538 Vigorito, A.C., 1181 Vijnovich Baron, A., 1422 Vikkula, M., 0922 Villa, M.R., 0113 Villalba, J.M., 0469 Villani, L., 0645 Villani, O., 0677, 0723 Villarón, E., 0328, 0426 Villarubia, J., 0681 Villa-Treviño, S., 1212 Villegas, A., 0807, 1137, 1152, 1391 Villeval, J.L., 0249 Vilmer, E., 1100 Vilque, J.P., 1108 Vimercati, R., 0508, 0663
Vincenzi, C., 1060 Viniou, N.-A., 0179, 0393 Vink, J., 0481 Vinogradova, O.Yu., 1365 Vintila, M., 1204 Viola, A., 0051, 0765, 1350 Viola, C., 1329, 1526 Vioni-Niemeyer, A., 1549 Viprakasit, V., 1145 Virappane, P., 0053, 0998 Virgili, A., 0541, 0544, 1014 Virkus, J., 1027 Visani, G.T., 1154 Visani, G., 0496 Visco, C., 0121, 0717, 0863 Vitale, A., 0013, 0015 Vitek, A., 0965, 0994 Vitelli, G., 0518 Vitera Silva, M., 1313 Vitolo, U., 0392, 0406, 0408 Vivante, A., 1435 Vives, S., 0483 Viviani, S., 0392 Vlachaki, E., 0803, 1132, 1273, 1547 Vladareanu, A.M., 1398, 1468 Vladimirskaya, E., 1223 Vlahava, V.M., 0327, 0962 Vlamis, C., 1022 Vlcanova, K., 0985 Vlodavsky, I., 1230 Voegeli, A.C., 0537, 1052 Voegeli, D., 0352, 1028 Voelkl, M., 0841 Vogel, C., 1241 Vogelsinger, H., 0214 Voglova, J., 0669 Voican, I., 1398, 1468 Voigt, W., 1331 Volcovets, N.D., 0162 Völk, M., 1549 Völker, U., 0148 Volkert, A.D.G., 0321 Volková, Z., 0959, 1044 Vollot, F., 0354 Voltarelli, J.C., 1463 Vom Dahl, S., 0734, 0735, 1115 Von Eggeling, F., 0129 Von Laer, M.D., 0420 Von Lilienfeld-Toal, M., 0227, 0229, 0264, 0265, 0266, 0267 Von Mackensen, S., 0603, 0769, 0771 Von Neuh<strong>of</strong>f, N., 0022 Von Schilling, C., 1140 Vorlicek, J., 0262, 0277 Vormittag, R., 0347, 0349, 0574, 0878, 0880 Vorob’ev, A., 1216 Vorobyev, I.A., 0740 Voronkova, E., 0818 Voskaridou, E., 0796, 0914 Voso, M.T., 0635, 1023 Vrana, M., 0447 Vranova, V., 0136 Vrbacky, F., 1487 Vroblova, V., 0949 Vrtala, S., 0311 Vrzalova, A., 0134 Vukosavljevic, T., 0396 Vukovich, T., 0347 Vyas, P., 0231 Vyatkin, I., 1437 Vygovska, Y.I., 1252 Vysotskaya, L., 1496 Vyzantiadis, T., 0638, 1263, 1418 W Wach, M., 1349 Wachowiak, J., 0071 Wadenvik, H., 0542, 0548 Wagdorn, K., 0551 Wagner, J.E., 0436 Wagnerova, B., 0208 Wahlstrom, A.M., 0475, 0924 Walewski, J., 0181, 0410 Waller, C. F., 0412 Walrafen, P., 0383 Wal<strong>the</strong>r, R., 0148 Waly, M., 1397 Walz, C., 0534, 0545 Wang, C.H., 0228 Wang, J.-Z., 0450 Wang, L.H., 0532 Wang, S., 1229 Wang, S.Y., 0563, 1178 Wang, X., 0772 Wang, Y., 0128, 0330 Ward, A., 0237 Warrington, R., 0211 Warzocha, K., 0120, 0618 Wasik-Szczepanek, E., 1342, 1349 Wassmann, B., 0375 Watanaboonyongcharoen, P., 1117 Watson, A.-M., 0660 Watts, M., 0507 Watzinger, F., 0367 Waultier, A., 1290 Wawrzyniak, E., 0493 Webersinke, G., 0164 Webster, D., 0596 Wegener, W.A., 0409 Wegh<strong>of</strong>er, M., 0311 Wegrzyn, J., 0618 Wehbe, R., 0795, 0811, 1400 Wehler, T.C., 0419 Wei, Y., 0542, 0548 Weichsel, R., 0320 Weidmann, E.W., 0308 Weigmann, A., 0384 Weiler, S., 0214 Weinmann, P., 0639 Weinreb, N., 0735, 1115 Weise, A., 0129 Weiss, D., 1229 Weiss, L., 1097 Weissinger, E.M., 0194, 0210, 0625, 1262 Weitzman, A., 0554, 0555, 0556, 0557, 0860, 0861 Wells, D.A., 0220 Wells, R., 0227, 0229 Welte, K., 0371, 0440 Weltermann, A., 0355, 0882 Wen, S., 0059 Wendl, C., 0925 Weng, L., 1025 Wennerås, C., 1265 Wennström, M.K., 1265 Werczynska, M., 1378 Wernig, G., 0414 Weßendorf, S., 0010 West, M., 0775 12 th <strong>Congress</strong> <strong>of</strong> <strong>the</strong> <strong>European</strong> <strong>Hematology</strong> Association Whetton, A.D., 0530 White, D., 0907 Whitman, S.P., 0396 Whittaker, S., 0456 Whittle, A.M., 0607 Wiater, E., 0263 Widmann, R., 0653 Wiecha, O., 0586 Wieczorek, L., 0444, 0891 Wieczorek, M., 0640 Wieczorkiewicz, A., 1434 Wiedenmann, E., 0694 Wiefelspütz, J., 1076 Wiehe, J.M., 0189 Wiener, C., 0355 Wierda, W.G., 0363, 0364 Wiernik, P.H., 0381 Wierzbowska, A., 0493 Wiesbauer, F., 0652 Wieser, R., 0405 Wiesneth, M., 0189 Wiest, D., 0416 Wijermans, P., 0233 Wijkhuis, A., 0421 Wiktor-Jedrzejczak, W., 0263 Wildenberger, K., 0563 Wilkens, L., 0240 Wilkens-Aktürk, E, 0368 Will, B., 0239, 0412, 0415, 0445 Willems, L., 0231 Willemze, R., 0369, 0715 Williams, B., 1220 Williams, D., 0560, 0760 Williams, L., 0772 Williams, M., 0444 Williams, S., 0339 Williams-Truax, R., 0153 Willmann, M., 1360 Wimmer, A., 0925 Wimperis, J., 0708 Winkler, D., 0099, 0108, 0118, 0909 Winkler, S., 1112 Winnisch<strong>of</strong>er, S.M.B., 0479, 0632, 1048 Winter, J.N., 1470 Wiseman, H., 1385 Wisløff, F., 0047 Wittnebel, S., 0617 Wittner, N., 0022 Witz, F., 0040 Witzens-Harig, M., 0010, 0270, 0271, 0297, 0298 Wlasiuk, P., 0511, 1342 Wlazlowski, M.W, 0071 Wlodarska, I., 0442 Woehrer, S., 0864 Woelfel, C., 0419 Woelfel, T., 0419 Woessner, S., 1137 Wohrer, S.W., 0711 Wojakowski, L., 0586 Wojciechowska, M., 1434 Wójcik, D., 0585 Wojnar, J., 0595, 0640 Wojtkowska, M., 1102 Wolf, H.-H., 1331 Wolf, H.W., 0308 Wolfrum, S., 0270 Wolowiec, D., 0273, 0981, 1111 Wolschke, C., 0584 Wolvers-Tettero, I., 0095 haematologica/<strong>the</strong> hematology journal | 2007; 92(s1) | ak
- Page 1 and 2:
haematologica the hematology journa
- Page 3 and 4:
Information for readers, authors an
- Page 5 and 6:
EHA Executive Board E. Hellström-L
- Page 7 and 8:
Poster session I POSTER SESSION POS
- Page 9 and 10:
12 th Congress of the European Hema
- Page 11 and 12:
dasatinib. Methods. We studied Ikar
- Page 13 and 14:
Expression of the oncogene H-Ras an
- Page 15 and 16:
is the gene for the erythropoietin
- Page 17 and 18:
safety of a slow-release liposomal
- Page 19 and 20:
0029 OUTCOME OF THE TREATMENT OF AD
- Page 21 and 22:
drug-induced apoptotic response of
- Page 23 and 24:
41% in the PI3K- group (p=0.001). I
- Page 25 and 26:
Acute myeloid leukemia - Clinical I
- Page 27 and 28:
to 60 years (n=116, or 72%) receive
- Page 29 and 30:
0056 PROGNOSTIC SIGNIFICANCE OF FLT
- Page 31 and 32:
Anemia and Bone marrow failure 0061
- Page 33 and 34:
tified with the current protocol. S
- Page 35 and 36:
new cases of lead poisoning due to
- Page 37 and 38:
icance, from baseline to week 6 (p
- Page 39 and 40:
0086 THROMBELASTOGRAPHIC CHART RELI
- Page 41 and 42:
trials. The aim of this retrospecti
- Page 43 and 44:
tant function in this disease, nega
- Page 45 and 46:
ed to a favorable outcome. Bialleli
- Page 47 and 48:
stronger levels of p21 in the cell
- Page 49 and 50:
hematological centers in one countr
- Page 51 and 52:
ure 1). Conclusions. Results for re
- Page 53 and 54:
patients. After a median follow-up
- Page 55 and 56:
Cytogenetics and Molecular diagnost
- Page 57 and 58:
0135 ROUTINE DETECTION OF CYTOGENET
- Page 59 and 60:
(MMolR, defined as a BCR-ABL x 100
- Page 61 and 62:
0146 ARSENIC TRIOXIDE INDUCES ACCUM
- Page 63 and 64:
tinguish between genotypic B-cell l
- Page 65 and 66:
Genomics and proteomics 0158 PLASMA
- Page 67 and 68:
0164 EVALUATION OF MULTIPLEX LIGATI
- Page 69 and 70:
each patient’s replicate conditio
- Page 71 and 72:
0174 RELATION BETWEEN LOW PML-RARα
- Page 73 and 74:
0179 ESHAP VS GIN AS SALVAGE AND MO
- Page 75 and 76:
Immunology and gene therapy 0184 EA
- Page 77 and 78:
Cell viability was not affected by
- Page 79 and 80:
month is not relevant to chronic Gv
- Page 81 and 82:
Infection and supportive care I 020
- Page 83 and 84:
0206 POTENTIAL ROLE OF CMV IN THE O
- Page 85 and 86:
3H-thymidine uptake in cell culture
- Page 87 and 88:
0217 TUBERCULOSIS AMONG A COHORT OF
- Page 89 and 90:
0222 COMPARISON OF IWG 2006 AND IWG
- Page 91 and 92:
tem (IPSS) to h-MDS was also invest
- Page 93 and 94:
PCH97-19) were studied. Conventiona
- Page 95 and 96:
of erythroid colonies was reduced i
- Page 97 and 98:
0245 POTENT AND SELECTIVE INHIBITIO
- Page 99 and 100:
0250 INACTIVATION OF SUPPRESSOR OF
- Page 101 and 102:
Bortezomib 1.3 mg/m 2 days 1,4,8,11
- Page 103 and 104:
Response was defined according to E
- Page 105 and 106:
G-CSF can be used in neutropenic pa
- Page 107 and 108:
ence and functional activity of CD8
- Page 109 and 110:
itating tumor development, or engag
- Page 111 and 112:
phoma and SNT-13, -15 were establis
- Page 113 and 114:
usage (2/20 ie 10%) were observed.
- Page 115 and 116:
0294 MYCOSIS FUNGOIDES. IMMUNOHYSTO
- Page 117 and 118:
(range, 1-6) and 11 treatment cycle
- Page 119 and 120:
0306 RISK-ADAPTED IMMUNOCHEMOTHERAP
- Page 121 and 122:
functional activity was confirmed b
- Page 123 and 124:
No major toxicity, neither hematolo
- Page 125 and 126:
enewal potential of X-RAR-positive
- Page 127 and 128:
(50-99) respectively. Serial analys
- Page 129 and 130:
cell-interaction, adhesion and acti
- Page 131 and 132:
0340 ALTERED FIBRIN CLOT STRUCTURE
- Page 133 and 134:
Conclusions. This study demonstrate
- Page 135 and 136:
0354 FACTOR V LEIDEN HOMOZYGOUS GEN
- Page 137 and 138:
Results. From July 2005 through Mar
- Page 139 and 140:
0364 CLINICAL EFFICACY OF OXALIPLAT
- Page 141 and 142:
one marrow and peripheral blood ste
- Page 143 and 144:
ecently suggested (Boissel et al.,
- Page 145 and 146:
0378 SAFETY AND EFFICACY OF THE TER
- Page 147 and 148:
Cytogenetics and molecular diagnost
- Page 149 and 150:
0385 CYTOPLASMIC MUTATED NUCLEOPHOS
- Page 151 and 152:
0390 ELTROMBOPAG RAISES PLATELET CO
- Page 153 and 154:
factor for the achievement of CR wa
- Page 155 and 156:
The cases of RAS showed two peaks o
- Page 157 and 158:
is 85%. Seven out of the 25 relapse
- Page 159 and 160:
0409 FRACTIONATED RADIOIMMUNOTHERAP
- Page 161 and 162:
0414 COMPARATIVE ANALYSIS OF THE CO
- Page 163 and 164:
successfully managed with GM-CSF di
- Page 165 and 166:
49% for PCR positive patients (95%
- Page 167 and 168:
+8 (1 PR+1 HI) and 14/24 pts with c
- Page 169 and 170:
(e.g. bcr-abl leading to CML). CSC
- Page 171 and 172:
0438 TERC MUTATIONS ANALYSIS IN PAT
- Page 173 and 174:
observed in all mice. Analysis of l
- Page 175 and 176:
ex-vivo expansion of HUCB-derived H
- Page 177 and 178:
ic kidney disease in univariate or
- Page 179 and 180:
One hundred eleven CN AML patients,
- Page 181 and 182:
to asses intestinal epithelial dama
- Page 183 and 184:
genesis of acute myeloid leukaemia
- Page 185 and 186:
polymorphism at nucleotide 4889 of
- Page 187 and 188:
expression along with a decreased C
- Page 189 and 190:
0487 MUTATIONAL STATUS OF NUCLEOPHO
- Page 191 and 192:
previously reported, a single cours
- Page 193 and 194:
0497 SINGLE AGENT CLORETAZINE (VNP4
- Page 195 and 196:
ly received melphalan-based chemoth
- Page 197 and 198:
were similar among the 3 groups. Ho
- Page 199 and 200:
Methods. Several read-out systems w
- Page 201 and 202:
0518 SERUM AND CELLULAR EXPRESSION
- Page 203 and 204:
0523 DNA REPAIR INHIBITION IN RESTO
- Page 205 and 206:
held true when BMI-1 expression was
- Page 207 and 208:
Ph + cells in the bone marrow). We
- Page 209 and 210:
derivative chromosome (4p16, 7p14,
- Page 211 and 212:
0545 STABILIZED BONE MARROW IS NOT
- Page 213 and 214:
obtained in low (Sokal) risk patien
- Page 215 and 216:
median dose intensity being 800 (21
- Page 217 and 218:
from pivotal clinical trials. Metho
- Page 219 and 220:
Cytogenetics and Molecular diagnost
- Page 221 and 222:
to set up and optimize a D-HPLC-bas
- Page 223 and 224:
0576 WESTERN BLOT IDENTIFICATION OF
- Page 225 and 226:
Basic disease was AML (n=5), ALL (n
- Page 227 and 228:
0588 EXTRACORPOREAL PHOTOPHORESIS F
- Page 229 and 230:
acquire a cytolytic capacity agains
- Page 231 and 232:
informed vignettes describing healt
- Page 233 and 234:
using CHOP-21 in the UK, pegfilgras
- Page 235 and 236:
0609 SOFT TISSUE COMPLICATIONS IN P
- Page 237 and 238:
inding lectin (MBL) gene by polymer
- Page 239 and 240:
all infection rate (p=0.12) as well
- Page 241 and 242:
Myelodysplastic syndromes II 0623 M
- Page 243 and 244:
formation (in total 28 samples). Ti
- Page 245 and 246:
sion. In addition, confocal analysi
- Page 247 and 248:
Myeloproliferative disorders - Clin
- Page 249 and 250:
open-label, multi-centre study enro
- Page 251 and 252:
iopsies after 6 and 12 months treat
- Page 253 and 254:
Myeloproliferative disorders Chroni
- Page 255 and 256:
ash, muscolar cramps, diarrhoea, he
- Page 257 and 258:
induced significant apoptosis (mean
- Page 259 and 260:
Myeloma and other monoclonal gammop
- Page 261 and 262:
the therapy of choice for POEMS is
- Page 263 and 264:
er patient does not indicate such t
- Page 265 and 266:
Myeloma and other monoclonal gammop
- Page 267 and 268:
secutive patients with MM, referred
- Page 269 and 270:
whether gene expression values may
- Page 271 and 272:
0705 THE SHIFT OF TREATMENT FOR NAS
- Page 273 and 274:
0710 CLINICO-PATHOLOGICAL FEATURES,
- Page 275 and 276:
patients presented a stage IV disea
- Page 277 and 278:
plete remission or recurrent diseas
- Page 279 and 280:
known at NHL diagnosis, were includ
- Page 281 and 282:
0731 THE IMPACT OF HIV ON NON-HODGK
- Page 283 and 284:
patients had died of their underlyi
- Page 285 and 286:
scripts and proteins most affected
- Page 287 and 288:
modulated after 24 h (37 up- and 59
- Page 289 and 290:
0753 A SUSTAINED REMISSION OF IDIOP
- Page 291 and 292:
and treatment, has rarely been syst
- Page 293 and 294:
uncontrolled massive bleeding affec
- Page 295 and 296:
Results. A total of 396 patients we
- Page 297 and 298:
C30 questionnaire, and the correspo
- Page 299 and 300:
wave length of light of reflected r
- Page 301 and 302:
0783 PREVALENCE OF MEMBRANE PROTEIN
- Page 303 and 304:
erozygous mother has a more severe
- Page 305 and 306:
0794 CARDIAC MANIFESTATIONS IN A BR
- Page 307 and 308:
0799 INEFFECTIVE ERYTHROPOIESIS IN
- Page 309 and 310:
p=0.014 and p=0.003, respectively).
- Page 311 and 312:
0809 CURRENT APPROACH TO CHELATION
- Page 313 and 314:
Thrombosis II 0814 UNSUSPECTED PULM
- Page 315 and 316:
the 97.5th percentile (5.2 U/mL) ge
- Page 317 and 318:
symptoms of DVT, 3 (7.89%) previous
- Page 319 and 320:
Transfusion medicine and vascular b
- Page 321 and 322:
tions (most bacterial, 2 malaria, 6
- Page 323 and 324:
0844 INCREASED LEUKOCYTE-PLATELET I
- Page 325 and 326:
0851 CORD BLOOD DERIVED MESENCHYMAL
- Page 327 and 328:
SIMULTANEOUS SESSION II Chronic mye
- Page 329 and 330:
0862 COMPARISON OF DASATINIB TO HIG
- Page 331 and 332:
0867 COMPREHENSIVE GERIATRIC ASSESS
- Page 333 and 334:
0872 MN1 INDUCES LEUKEMIA IN MICE A
- Page 335 and 336:
0877 PAX5/TEL TRANSDUCED PRE-BI CEL
- Page 337 and 338:
0882 CISPLATIN INDUCES THROMBIN GEN
- Page 339 and 340:
have an early manifestation of typi
- Page 341 and 342:
0892 INTEGRATION OF GENOME WIDE SNP
- Page 343 and 344:
0897 THE PHENOTYPE OF JAK2V617F MUT
- Page 345 and 346:
gest diverse sequences of NPM mutan
- Page 347 and 348:
2004 to January, 2006. At enrollmen
- Page 349 and 350:
with a p value of ≥ 0.10. Sets of
- Page 351 and 352:
BRIC 126 and 4N1K) in cells lacking
- Page 353 and 354:
sclerosis[NS] and 12 Mixed cellular
- Page 355 and 356:
0927 MK-0457, A NOVEL MULTIKINASE I
- Page 357 and 358:
Publication Only 0933 CLINICAL FEAT
- Page 359 and 360:
HSCT from the available Asian as we
- Page 361 and 362:
that the incidence of JAK2 mutation
- Page 363 and 364:
without type 2 diabetes. Methods. T
- Page 365 and 366:
pts (38.8%) that were isolated (abs
- Page 367 and 368:
y using the Miltenyi CD34 isolation
- Page 369 and 370:
0969 COMPARISON OF CD25 IMMUNOHISTO
- Page 371 and 372:
cytes was 24 days (range 8-32 days)
- Page 373 and 374:
a cytogenetic hallmark for M4/M5 su
- Page 375 and 376:
normal human BM B progenitor cells
- Page 377 and 378:
0994 INCIDENCE OF INVASIVE ASPERGIL
- Page 379 and 380:
3 of disease relapse.TRM at day+100
- Page 381 and 382:
survival of five years. This dismal
- Page 383 and 384:
1011 FLOW CYTOMETRIC DNA INDEX AND
- Page 385 and 386:
1018 THE EFFECT OF THE SUGARBAKER P
- Page 387 and 388:
1024 KIR/HLA CLASS I MISMATCHING AN
- Page 389 and 390:
ment details and thrombotic histori
- Page 391 and 392:
1036 INCIDENCE AND SPECTRUM OF INFE
- Page 393 and 394:
tinely by our stem cell lab prior t
- Page 395 and 396:
tion to a translocation t(5;14)(q35
- Page 397 and 398:
ment of CML and induces a high rate
- Page 399 and 400:
due to reactivation and/or progress
- Page 401 and 402:
1063 ABNORMAL METHYLATION STATUS OF
- Page 403 and 404:
1069 CLINICAL RELEVANCE OF REGULATO
- Page 405 and 406:
1076 SERUM LEVELS OF SOLUBLE HLA CL
- Page 407 and 408:
patient is still undergoing intensi
- Page 409 and 410:
nificant MVD differences were detec
- Page 411 and 412:
dictor of OS (p=0.004). High dose t
- Page 413 and 414:
1099 ALTERATIONS IN THE NATURAL KIL
- Page 415 and 416:
1105 CYTOGENETIC ABNORMALITIES IN 3
- Page 417 and 418:
1110 CONSTITUTIVE ACTIVATION OF STA
- Page 419 and 420:
efficacy results with a well-tolera
- Page 421 and 422:
unmutated VH genes, and high and lo
- Page 423 and 424:
Aims. Aim of this study was to pred
- Page 425 and 426:
tested across a wide range of human
- Page 427 and 428:
were incidentally diagnosed (52%).
- Page 429 and 430:
ß2GP1 may be considered as determi
- Page 431 and 432:
characterized in 198 β thalassaemi
- Page 433 and 434:
1155 PLATELET AGGREGATION IN CHILDR
- Page 435 and 436:
to-pelvic or perineal trauma. No me
- Page 437 and 438:
in age. High prevalence of LBM amon
- Page 439 and 440:
ecause some of the patients were or
- Page 441 and 442:
of the drug is crucial to allow lon
- Page 443 and 444:
egarding cost analysis of ASCT in G
- Page 445 and 446:
ID Allo-BMT, 1 family one mismatche
- Page 447 and 448:
admitted to ICU were discharged des
- Page 449 and 450:
events -Postoperative states: 9,19%
- Page 451 and 452:
efficacy and decreased atherosclero
- Page 453 and 454:
1217 INCIDENCE OF EARLY STAGE IDIOP
- Page 455 and 456:
1691GA and 1 homozygous 1691AA. The
- Page 457 and 458:
1230 ASSOCIATION OF HEPARANASE GENE
- Page 459 and 460:
posed, was: DF = (CD43%+FMC7%+CD79b
- Page 461 and 462:
treatment of acute promyelocityc le
- Page 463 and 464:
loaded group and 35 (70%) were non-
- Page 465 and 466:
mild. Fas and soluble Fas ligand le
- Page 467 and 468:
1265 POSACONAZOLE THERAPY IN REFRAC
- Page 469 and 470:
ly express the cytoplasmic (inactiv
- Page 471 and 472:
findings confirmed the significant
- Page 473 and 474:
a less favorable prognosis. Interes
- Page 475 and 476:
disease (HD), 4 patients (9%) with
- Page 477 and 478:
1295 HEMOPHAGOCYTIC LYMPHOHYSTIOCYT
- Page 479 and 480:
phamide 750 mg/m 2 on day 1, vincri
- Page 481 and 482:
nomenon is unclear. It has been sug
- Page 483 and 484:
oped mild thrombocytopenia (platele
- Page 485 and 486:
gle dose of 54mg/m 2 rituximab furt
- Page 487 and 488:
patients (pts), 36 male, with acute
- Page 489 and 490:
esulting alterations of the endothe
- Page 491 and 492:
(range 1-7) and 28,6% of patients h
- Page 493 and 494:
three decades. In vivo, Ara-C is tr
- Page 495 and 496:
statistical analysis. Results. Seve
- Page 497 and 498:
Results. Though there was no recogn
- Page 499 and 500:
2% and 19% of patients with or with
- Page 501 and 502:
were older than 65 y) which can be
- Page 503 and 504:
1376 RESVERATROL INDUCED P53 MEDIAT
- Page 505 and 506:
median time of 21 days to reach >0.
- Page 507 and 508:
ly. Conclusions. 1. Combined intens
- Page 509 and 510:
to the presence of IVS1-6 mutation
- Page 511 and 512:
fy predictive factors for these abn
- Page 513 and 514:
acute leukemia. However, we cannot
- Page 515 and 516:
agents. They involve primarily the
- Page 517 and 518:
voriconazole for 2 months followed
- Page 519 and 520:
typed using a commercially availabl
- Page 521 and 522:
low up of ABL KD mutations’ level
- Page 523 and 524:
with development of BC/AP. 2. EVI-1
- Page 525 and 526:
1447 THE IMPACT OF DISPARITY IN SHO
- Page 527 and 528:
three had visual field defects, two
- Page 529 and 530:
acquired mutation most prone to cau
- Page 531 and 532:
1466 ROS GENERATION AND APOPTOSIS I
- Page 533 and 534:
1473 DIARRHEIC SYNDROME, A CLINICAL
- Page 535 and 536:
gene fusion is an independent progn
- Page 537 and 538:
1484 EPIDEMIOLOGY AND RESPONSE TO T
- Page 539 and 540:
1492 FREQUENCY OF MEDITERRANEAN GLU
- Page 541 and 542: immune globulin was administered at
- Page 543 and 544: maintained on Imatinib 400 mg. Afte
- Page 545 and 546: Hodgkin’s disease is well known,
- Page 547 and 548: gram provided a unique chance to de
- Page 549 and 550: even when ADP-induced plt activatio
- Page 551 and 552: medullary involvement of multiple m
- Page 553 and 554: 1540 ADMINISTRATION OF G-CSF AND CH
- Page 555 and 556: 1548 QUALITY ANALYSIS OF THE MULTID
- Page 557 and 558: Index of authors A Aapro, M., 0377,
- Page 559 and 560: Bahr, J., 0148 Bai, M., 1551 Baia,
- Page 561 and 562: Bottini, P.V., 1181 Botto, B., 0408
- Page 563 and 564: Chaidos, A., 0456, 0498, 0599, 0686
- Page 565 and 566: De Keersmaecker, K., 0442, 0875 De
- Page 567 and 568: El-Sharkawy, N., 0016 Elwahidi, G.,
- Page 569 and 570: Garcia-Frade, J., 0346, 0680, 1105
- Page 571 and 572: H Haas, N., 0742 Haas, O.A., 0001,
- Page 573 and 574: Jaksic, B., 0127, 0446 Jaksic, O.,
- Page 575 and 576: Körmöczi, G., 0848 Kornblau, S.,
- Page 577 and 578: Lin, L.-I., 0030, 0484 Lin, T., 012
- Page 579 and 580: Massé, A., 0249 Massó, P., 1287,
- Page 581 and 582: Musto, P., 0254, 0401, 0422, 0569,
- Page 583 and 584: Papadavid, E., 1442 Papageorgiou, E
- Page 585 and 586: Probatova, N., 0704 Prochazka, V.,
- Page 587 and 588: Rykavicin, O., 0504 Ryningen, A., 0
- Page 589 and 590: Sirard, C., 0127, 0128 Sirigou, A.,
- Page 591: Thiebaut, A., 0454 Thieblemont, C.,
- Page 595 and 596: Zouabi, H., 0503, 0999 Zoumbos, N.C
- Page 597 and 598: 12 th Congress of the European Hema
- Page 599 and 600: 12 th Congress of the European Hema
- Page 601 and 602: 12 th Congress of the European Hema
- Page 603: 12 th Congress of the European Hema